Drug Profile
Phycocyanobilin - Center for Genetic Engineering and Biotechnology/Heber Biotech
Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology; Heber Biotec
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cerebral infarction
Most Recent Events
- 31 Aug 2023 Discontinued - Preclinical for Cerebral infarction in Cuba (unspecified route), prior to August 2023 (Center for Genetic Engineering and Biotechnology pipeline, August 2023)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Cerebral-infarction in Cuba
- 01 Dec 2014 Preclinical trials in Cerebral infarction in Cuba (unspecified route)